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Abstract
Acute coronary syndrome (ACS) continues to be the most common cause of death in the
United States, and nearly every 34 seconds one American has a coronary event. Based on 12lead electrocardiogram (ECG) findings myocardial infarction (MI) patients are treated, according
to guidelines, emergently with reperfusion therapy if presenting with ST elevation myocardial
infarction (STEMI), versus delayed revascularization if presenting with non-ST elevation
myocardial infarction (NSTEMI). However, the evidence shows there is a lack of recognition of
which patients require immediate catherization utilizing the current guidelines. In recent years,
approximately 70% of acute MI (AMI) patients are classified as NSTEMI. Furthermore, it has
been observed that approximately 30% of NSTEMI patients have total occluded coronary
arteries (TOCA) on angiography yet face a delayed intervention approach that contributes to
worsened clinical outcomes.
The current STEMI/NSTEMI paradigm lacks the accuracy in triaging patients who have
a suspected acute coronary occlusion (ACO) or near occlusion, with insufficient collateral
circulation, whose myocardium is at imminent risk of irreversible infarction without immediate
reperfusion. A more recent emerging paradigm to determine who warrants immediate
reperfusion is ACO-MI/Non-ACO-MI or Occlusion Myocardial Infarction (OMI) versus NonOcclusion Myocardial Infarction (NOMI) for short. To answer whether the OMI/NOMI
paradigm was superior to STEMI/NSTEMI in evaluating ACS patients, a literature review was
conducted primarily utilizing the database PubMed, and certain full-text articles were obtained
through Augsburg University’s interlibrary loan system. Overall, literature shows limitations of
the current STEMI/NSTEMI paradigm and shows that OMI/NOMI paradigm has superior
diagnostic accuracy and earlier recognition abilities for treating patients that present with ACS.
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Introduction
Acute coronary syndrome (ACS) continues to be the leading cause of death in Americans
with a coronary event occurring every 34 seconds [1]. The diagnosis and management of
suspected ACS patients is done through primarily risk stratifying according to ECG findings
showing either ST segment elevations (STEMI), or non-ST segment elevations (NSTEMI) to
determine use of early invasive management or early conservative strategy. In addition to ECG
findings, history of presenting symptoms and biochemical markers of myocardial necrosis are
also utilized to further classify suspected ACS patients. The current STEMI/NSTEMI paradigm
in treating presentations of ACS can be traced back to the early 2000s, in part due to research
revealing that the subset of patients presenting with ST elevations on their ECGs had mortality
benefits versus those who did not show ST segment elevations when given thrombolytics [2].
Although the research should have been taken as an initial step into risk stratifying patients to
determine use of emergent reperfusion therapy, the outcome was an almost synonymous
association between the surrogate ECG marker of STE and acute coronary occlusions (ACO).
Historically, the STEMI/NSTEMI guideline’s development and refinement have been done
through flawed methodology, failing to utilize angiographic evidence to accurately determine
which patients had occluded arteries with imminent irreversible myocardial damage requiring
emergent reperfusion therapy [2-4]. With the current paradigm, the guidelines advocate for
patients presenting with NSTEMI to primarily await delayed angiography and only seek
emergent (<2 h) reperfusion therapy if deemed high-risk [5]. Approximately 30% of patients that
fit NSTEMI criteria have unrecognized total occluded coronary arteries (TOCA) on delayed
angiogram [6-7]. The delay in diagnosis and treatment results in increased morbidity, short-, and
long-term mortality of patients. Furthermore, there is an increasing incidence of NSTEMI being
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recorded worldwide and in recent years approximately 70% of AMI patients are classified as
NSTEMI [8-9]. However, STEMI criteria have a limited diagnostic accuracy, missing nearly
one-third of ACO, and causing a substantial amount of false catherization laboratory activations
[10]. In addition, our understanding of ECG changes indicative of ACO have expanded and
include minor STE not fulfilling STEMI criteria, STE disproportionate to preceding QRS,
unusual patterns with contiguous leads showing opposite ST deviations, and some patterns not
showing STE at all. Attempts at integrating these other ECG findings indicative of ACO into
terms such as “STEMI equivalents”, fail at gaining widespread understanding.
For reasons outlined above, a gap in treating NSTEMI patients with ACO clearly exists,
and thus a call for a paradigm shift to change the dichotomization of ACS into a more direct
pathological understanding has been proposed. The proposed alternative paradigm to
STEMI/NSTEMI is ACO-MI/non-ACO-MI or Occlusion Myocardial infarction (OMI) versus
Non-Occlusion Myocardial Infarction (NOMI) for short. Simply put, do they present with
occluded or near occluded coronary arteries with imminent myocardial damage requiring
immediate intervention or not. By changing the paradigm to OMI/NOMI, diagnosis does not
solely rely on ECG findings, which can be inconclusive, but includes clinical suspicion, ongoing
symptoms, biomarker elevation, echocardiography, computed tomography, and conventional
angiography. It is hypothesized that by transitioning to OMI/NOMI model for the evaluation of
acute coronary syndrome in adult emergency department patients results in improved outcomes
compared to the contemporary STEMI/NSTEMI paradigm. Objectives of this paper include
outlining current ACS management, the limitations and historical development of
STEMI/NSTEMI, and present the OMI/NOMI model and analyze how it compares.
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Background
Current ACS Classification/Management
When discussing suspicion for acute myocardial ischemia or infarction (AMI) an
umbrella term of acute coronary syndromes (ACS) is traditionally utilized. Under the current
classification system of ACS refers to one of three clinical syndromes: unstable angina (UA),
non-ST-segment elevation myocardial infarction (NSTEMI), or ST-segment elevation
myocardial infarction (STEMI). The leading symptom in patients suspected of ACS is acute
chest discomfort described as pain, pressure, tightness, and burning [5]. In addition, symptoms
can include dyspnea, epigastric pain, and radiating pain. Suspected ACS patients ideally undergo
a baseline resting ECG within 10 minutes of presentation two differentiate two types of patients
with risk of myocardial infarction. Based on 12-lead ECG findings, patients are assigned to
STEMI, if ST segment elevation is noted and are recommended to undergo immediate
reperfusion by primary percutaneous coronary intervention (PCI) (door-to-balloon time within
90 minutes), or fibrinolytic therapy if PCI is not available [11]. Patients with acute chest pain
discomfort but no persistent ST elevated ECG are termed NSTEMI or UA, until positive serial
cardiac markers rule in NSTEMI and rule out UA. NSTEMI patients are to undergo immediate
invasive strategy (<2 hrs) only if deemed high-risk, which can be characterized by recurrent or
ongoing chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and
hemodynamic or electrical instability regardless of ECG or biomarker findings. Conventional
teaching is that STEMI is generally regarded as reflecting an acute total or subtotal coronary
occlusion completely interrupting blood supply and causing transmural ischemia. While
NSTEMI is considered cardiomyocyte necrosis due to acute partial occlusion of a coronary
vessel causing incomplete interruption of blood supply causing non-transmural (subendocardial)

OMI/NOMI Paradigm 7

ischemia. However, it has been observed that totally occluded coronary arteries (TOCA) occurs
among NSTEMI patients as well, and two recent meta-analyses reported approximately 30% of
the patients diagnosed with NSTEMI had TOCA [7,12-13].
The diagnosis of AMI, (cardiomyocyte necrosis), in a clinical setting consistent with
myocardial ischemia, is met when the following criteria are met; detection of an increase and/or
decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin (hs-cTn) T or I,
with at least one value above the 99th percentile of the upper reference limit and at least one of
the following: 1. Symptoms of myocardial ischemia. 2. New ischemic ECG changes.
3. Development of pathological Q waves on ECG. 4. Imaging evidence of loss of viable
myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic
etiology. 5. Intracoronary thrombus detected on angiography or autopsy [11].
The increased access to high sensitivity troponin assays has led to an increased incidence
rate of NSTEMI being recorded worldwide, as well as, nearly 70% of AMI patients being
classified as NSTEMI in the United States [8-9]. Several definitions of AMI based upon
assumed cause exist, the most common being Type 1 MI, which is characterized by
atherosclerotic plaque disruption that results in intraluminal thrombus formation that impedes
myocardial blood flow leading to myocardial necrosis. Type 2 MI is a consequence of mismatch
between oxygen demand and oxygen supply that is caused by a condition other than plaque
instability. Type 2 MI etiologies include hypotension, hypertension, tachyarrhythmias,
bradyarrhythmias, anemia, hypoxemia, coronary artery spasm, spontaneous coronary artery
dissection, coronary embolism, and coronary microvascular dysfunction. Most Type 1 and Type
2 etiologies present as NSTEMI, however, can present as STEMI as well [14]. Type 3 MI
involves patients with unexpected death before biomarkers are drawn or appear in the blood.
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Type 4 MI is associated with percutaneous coronary intervention (PCI). Finally, type 5 MI is
from coronary artery bypass graft surgery (CABG).
It is generally understood that invasive revascularization interventions are most useful in
a Type 1 MI etiology. To maximize benefits of such interventions, deciding whether it should be
done immediately/emergent (within 2 h), early (within 24 h), or delayed (within 25-72 h), and
the selection of approach (PCI or coronary artery bypass grafting (CABG) need to be made as
early as possible. Angiographic evidence is utilized to classify coronary artery patency using the
TIMI Grade Flow scoring system. Grade 3 is normal flow with full perfusion, Grade 2 is delayed
flow with full perfusion, Grade 1 is penetration without distal perfusion, Grade 0 is complete
occlusion. It is the patients that have either a full occlusion, or near-occlusion with insufficient
collateral circulation with imminent risk of irreversible infarction that benefit from emergent
reperfusion therapy. Those whose myocardium is at risk, but not imminently, can be managed
with medical therapy including antiplatelets, anticoagulants, and/or delayed reperfusion.
Contemporary triage risk scores are utilized in identifying higher-risk patients that
present with ACS to aid in risk stratification. The TIMI (Thrombolysis in Myocardial Infarction)
score estimates adverse outcomes in patients with unstable angina or NSTEMI but can also be
used to risk stratify patients with presumed ischemic chest pain. Similarly, the GRACE (Global
Registry of Acute Coronary Events), estimates in-hospital, and 6-month to 3-year mortality in
patients with known STEMI, unstable angina/NSTEMI to determine morality risk and guide
more appropriate interventions. However, studies suggest neither TIMI risk score nor GRACE
risk scores can very accurately identity which patients’ angina symptoms are due to ACS, and
can only modestly identify NSTEMI patients with underlying TOCA who are at higher risk
[7,13,15]. Guideline’s recommendation of delayed reperfusion in NSTEMI patients results in a
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mean time to angiography or PCI being more than 24 h [7,13]. Emergent reperfusion is
recommended if NSTEMI patient is deemed high-risk, characterized by recurrent or ongoing
chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and hemodynamic or
electrical instability regardless of ECG or biomarker findings. There is also no difference in time
to angiography or PCI between NSTEMI patients with or without TOCA [13].
Historical Context of STEMI/NSTEMI Paradigm Development
Before the reperfusion era ushered in the STEMI/NSTEMI paradigm, the first established
MI paradigm was Q-wave/non-Q-wave MI dichotomy [16]. Retrospectively classifying patients
based on Q wave development on ECG, or sign of irreversible transmural loss of myocardium,
was the best available knowledge for the better part of the 20th century. The historical timeline of
major events providing insights into the pathogenesis and management of AMI leading up to the
reperfusion era is presented Fig. 1 [17]. The 1980s and early 1990s were defined by landmark
trials and meta-analyses showing IV fibrinolytics had substantial survival benefits and outcomes
for suspected ACS patients, especially when given early [2,18,19].
The randomized control studies evaluating fibrinolytics use in patients presenting with
AMI began to shift our paradigm from retrospective diagnosis and seldom treatment options, but
rather towards prospective identification and treatment. The 1994 Fibrinolytic Therapy Trialists’
(FTT) meta-analysis pooled data from 58,600 patients enrolled in 9 randomized control studies
using highly suspicious patients presenting with acute chest pain that were randomized to either
thrombolytics or placebo [2]. The average number of patients needed to treat to benefit one of
the patients expressed as NNT, was 56 from lytics compared to placebo, showing a significant
mortality benefit before performing any subgroup analysis. Subset analysis of the groups from
the RCTs was done to determine which groups had the highest benefit or harms. The subgroups
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were defined vaguely by ECG findings of “ST elevation (STE)”, “ST depression (STD)”, or
“Normal”. Only five of the RCTs had defined their version of STE, which had varying cutoffs
and methods of measurement. The definition of “Normal” and “STD” were not adequately
defined either. The remaining four of the nine trials did not use ECG for enrollment. Upon subset
analysis, STE was found to be the most closely associated ECG finding as an arbiter of
fibrinolytic administration which improved NNT for short term mortality from 56 to 43. On the
other hand, those subset groups defined as “Normal” or “STD” showed a non-significant trend
towards mortality harm expressed as number needed to harm (NNH), (NNH=143, 42). The metaanalysis helped identify that the poorly defined “STE” can be used as surrogate marker to predict
potential acute coronary occlusion (ACO) and thus mortality benefit from lytics than not looking
at the ECG at all. The meta-analysis did not use angiographic findings to identify which patients
had an ACO. In 2000, the ACC/AHA guidelines formally changed the paradigm from Q-wave
vs. non-Q wave MI to STEMI vs NSTEMI [20].
Research continued focusing on delineating what appropriate amount of STE was
deemed a STEMI and fine tuning it, but often failing to utilize angiographic evidence to
determine who indeed had an ACO. Menown et al., utilized ECG and biomarker findings using
1,190 subjects to determine that ≥ 2 STE in at least one of the anteroseptal leads, or ≥1mm in any
of the other leads which had a 56% sensitivity and 94% specificity for AMI vs no AMI [3]. The
study did correctly classify 83% of patients as having AMI, however not utilizing angiography
means patients without occlusion were included. The results suggest the approach can predict
AMI accurately, but the same cannot hold true for predicting ACO. The result of the study
instituted the First Universal Definition of MI and the first STEMI criteria findings: patients with
STE that had new or presumed new ST segment elevation in two or more contiguous leads with
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≥0.2 mV in leads V1, V2, or V3, or ≥0.1 mV in other leads. Patients without STE could have
findings indicative of ischemia that could progress to MI were STD, or T-wave abnormalities
that should be observed in two or more contiguous leads, or symmetric inversion of T waves
≥1mm in at least two contiguous leads [21]. Subsequent studies by Mcfarlane et al. and Wu et
al., found that ironically baseline STE was a common appearance among apparently healthy
adults who presumably did not have ACO [4,22]. Wu et al. even found that 2% of Chinese males
aged 18-40 had 3mm or more of J point elevation in V1 and V2 at baseline, which is at odds of
the first universal definition of MI [22]. Regardless, in 2004 the ACC/AHA recommended that
STE of ≥1mm in any two contiguous leads or adjacent limb leads warranted fibrinolytic therapy
with symptom onset within the prior 12 hours [23].
The Second Universal Definition of MI came about in 2007 after research showed that
implementing sex-based cutoffs for STEMI criteria would increase the sensitivity and specificity
of correlating ECG findings to elevated biomarkers [24-25]. The Second Universal Definition
recommended two contiguous leads with at least 1.0mm STE, except for leads V2-V3 which
requires 1.5mm in women and 2.0mm in men [25]. The definition was primarily based on what
Macfarlane et al. had found performing a logistic regression technique to revise the STEMI
criteria based on age and sex-based cutoffs, which increased sensitivity from 42% to 47% and
specificity from 96% to 99% when correlating the ECG findings to biomarker elevation [24]. No
angiographic evidence was utilized, so data on ACO patients was not reported.
In 2009, the current STEMI criteria were introduced with both age and sex-based cutoffs
for STE being, new ST-elevation at the J-point in 2 contiguous leads with the cut-point: ≥1 mm
in all leads other than leads V2–V3 where the following cut-points apply: ≥2 mm in men ≥40
years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age [26]. For STD and T-
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wave changes new horizontal or downsloping ST-depression ≥0.5 mm in 2 contiguous leads
and/or T inversion >1 mm in two contiguous leads with prominent R wave or R/S ratio >1 were
defined. These criteria were subsequently included into the 2012 development of the Third
Universal Definition of MI, with the addition of some minor reference that other ECG findings
like hyperacute T-waves can possibly represent AMI [27]. The ST-elevation criteria have
continued to be included in even the most recent 2018 fourth universal definition of MI [28].
STEMI criteria has become the guideline-based approach to diagnosing ACO with a notion that
it is the most accurate marker for determining ACO, and thus a marker for who needs emergent
reperfusion therapy.
STEMI/NSTEMI Paradigm is Inaccurate and Detrimental
Just as Q-wave/non-Q wave served as a surrogate ECG marker for MI previously,
STEMI/NSTEMI is currently serving that identical purpose as a marker of acute coronary
occlusion that fails to account for the underlying pathology. Keeping the underlying pathology in
mind, STEMI criteria fails to identify acute coronary occlusion accurately.
Schmitt et al. was one of the first to find the limitations of utilizing STEMI criteria [29].
A total of 1,788 patients with suspected AMI based on clinical symptoms and positive CK-MB,
were prospectively enrolled for emergent coronary angiography. In total 23% had confirmed
ACO (418/1788), and out of those 418 patients, 29% did not meet STEMI criteria. The least
sensitive measure of STEMI criteria was in those presenting with an acute left circumflex
occlusion which had a high miss rate of 50%. The PARAGON-B trial was a randomized control
study using 1,957 patients with non-STE ACS presentation [30]. It was found that 27% of those
patients had completely occluded culprit vessels on next day angiography. In addition, it was
found that these patients had larger infarcts (median peak creatine kinase–MB 4.3 vs 2.1 × upper

OMI/NOMI Paradigm 13

limit of normal, P < .0001) and higher risk adjusted 6-month mortality (hazard ratio 1.72, 95%
CI 1.07-2.79) despite similar in hospital treatment. Similar findings were found in the TRITONTIMI-38 randomized control trial for patients undergoing cardiac catherization, in which 26.2%
had completely occluded culprit arteries at the time of catherization [31]. Additionally, 48.4% of
those with occlusion, the culprit artery was the left circumflex. The 30-day incidence of
composite of death and MI was significantly higher in the occluded artery group and the median
time from ECG to PCI was 29.4 hours. Khan et al., performed a meta-analysis from seven
studies in which NSTEMI patients were prospectively enrolled and assessed for occluded culprit
arteries [32]. Out of 40,777 NSTEMI patients, 10,415 (25.5%) had total occluded coronary
arteries (TOCA) found on angiography an average of 24 hours after presentation. Furthermore,
these unrecognized ACO patients had increased risk of both MACE (major adverse
cardiovascular events) in the short and medium to long term, and all-cause mortality.
Overall, NSTEMI patients with unrecognized ACO face adverse cardiovascular events.
Even the most recent publications show that NSTEMI with ACO compared to NSTEMI without
ACO have increased mortality ratios, increased re-infarction rates, and increased mortality in the
short and long term [7,13]. The authors concluded better risk stratification tools are needed to
facilitate earlier revascularization and improving outcomes in NSTEMI patients with ACO,
because of the increased risks associated with missing the diagnosis [13].
Studies highlight a substantial amount of ACO patients present with subtle STE not
fulfilling current STEMI criteria. One study found that patients with angiographic evident ACO
presenting with subtle STE of (.1-1mm), 18.3% had not even a single lead with 1mm STE [33].
Despite having smaller infarcts, the subtle STE subgroup had more frequent multivessel disease,
larger delays to reperfusion, and was not associated with better outcomes. Smith et al.,
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retrospectively compared 143 subtle proven acute left anterior descending (LAD) occlusions and
found that 22% of patients (33) that had subtle LAD occlusion with a mean STE ≤1mm, 19
patients with no leads showing more than 1mm, and 8 patients with less than or equal to 1mm in
only 1 lead [34]. AM et al., analyzed 1,500 consecutive patients with angiographic complete or
near occlusion to determine if through re-reading their ECG they would meet STEMI criteria
[35]. Surprisingly, even with the bias of knowing these patients had ACO in addition to using a
more liberal cutoff of ≥ 1mm STE in any 2 contiguous leads, 28% (423) patients still did not
meet the criteria.
Another failure of utilizing STEMI ECG criteria is that it has poor accuracy among
clinicians and has poor interrater reliability for detecting ACO. McCabe et al., performed a cross
sectional survey using EM physicians and cardiologists to review 36 ECG for prospective
STEMI activation [36]. 24 of the ECGs were true positives (STEMI), while 12 of the cases had
no culprit lesion (no STEMI). Physicians were asked “based on the ECG above, is there a
blocked coronary artery present causing a STEMI?”. 124 physicians interpreted a total of 4,392
ECGs and showed that intrareader agreement (kappa) for ECG interpretation was 0.33, reflecting
poor agreement. Sensitivity to identify true STEMIs was 65% and specificity was 79% [36].
Interesting enough, even after adjusting for experience there was no difference in the odds of
overall accurate interpretation between specialties [36]. Other studies have also showed poor
interrater reliability and wide variations among experienced electrocardiographs in determining
which ECGs had STE with need for PCI from nonischemic STE [37-38]. Carley et al. showed
that even among physicians that commonly prescribe thrombolysis the observed STE magnitude
varied, because doctors use a wide variety of points on the ST segment to assess elevation [39].
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Most recently prospective cardiologist subjective evaluation revealed only 49% sensitivity for
predicting ACO [40].
In addition to failing to identify ACO, STEMI criteria leads to many false STEMI
activations. In one study out of 411 STEMI activations by EM physicians, 146 (36%) were
deemed false positive that did not warrant PCI [41]. In another study using 1,335 patients from
31 regional hospitals in Minnesota who presented with suspected STEMI and underwent
angiography, 187 (14%) did not have a clear culprit coronary artery, 9.5% did not have
significant coronary artery disease, and 11.2% had negative biomarkers [42].
The development of computerized diagnostic algorithms to assist in the interpretation of
ECG has been used in suggesting STEMI, but the research shows that even automated
interpretation has high rates of error [43-45]. The algorithms have a wide variation of false
positives (0-42%), and false negative results (22-24%). Hillinger et al., in a prospective
validation of current ECG criteria reported recently that sensitivity of computer algorithm
measurement was 21%, and for cardiologist-adjudicated STEMI was still remarkably low (35%)
[40]. The recommendation is that computer-assisted ECG interpretation should not be used as a
sole means to diagnose STEMI, but it still can bias physician judgement [46-47]. Furthermore,
computer interpretation basis is on STEMI criteria and can miss the subtle ST elevation, (which
may be significant in small amplitude QRS complexes), ST depression in aVL (which is
sensitive for inferior MI), and subtle signs of LAD occlusion like terminal QRS distortion [48].
Finally, if the computer interpretation reads “normal” it must be carefully interpreted because it
can miss the ischemic morphology (straight or convex ST segments, terminal T wave inversion,
down-up T waves, hyperacute T waves, and inverted U waves), and dynamic changes (subtle
changes, pseudonormalization of ST segments, or T-waves) [48-49].
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STEMI Paradigm Misses Other Findings
The final point towards why STEMI/NSTEMI fails as a paradigm for ACO is that it acts
as a cognitive roadblock. The words STEMI make one cognitively assume that STE is the only
ECG variable that matters, missing other subtleties of ECG interpretation [50]. For example,
proportionality of STE, STD, or T-wave size must be assessed relative to the QRS amplitude,
which is absent from STEMI/NSTEMI criteria [51]. With lower QRS voltage, the more
significant any STE/STD/T-wave size becomes.
Rules for determining subtle left anterior descending (LAD) coronary occlusion over
normal variant STE have been found to be very accurate utilizing a four variable formula
resulting in sensitivity of 86% and specificity of 92% for LAD occlusion [52]. Normal variant
STE is also shown to present with an S-wave or a prominent J-wave notch in both V2 and V3,
and absence of it is termed “terminal QRS distortion” seen only in LAD-ACO with a 100%
specificity [53]. In subtle inferior STE, looking at aVL, which is the only lead that is truly
opponent the inferior wall, and finding evidence of any STD is a sensitive, early sign of inferior
ACO [54-55].
STE due to secondary repolarization abnormalities have also been evaluated for more
diagnostic ECG findings of ACO. For example, modified Sgarbossa criteria have been evaluated
to accurately diagnose ACO in presence of left bundle branch block (LBBB) (sensitivity=91%,
specificity 90%), or ventricular paced rhythm (sensitivity=67%, specificity 99%) [56-57]. It has
been shown that STE >25% of the QRS amplitude can specifically be used for differentiating
STE due to ACO from STE due to left ventricular hypertrophy with sensitivity 64%, specificity
93% [58]. Rules for differentiating STE from post-MI ventricular aneurysm or pericarditis from
ACO have also been published with high sensitivity (91%, 98%) and specificity (81%, 100%)
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[59-60]. Shaikh et al., has recently proposed ACS patience presenting with new onset right
bundle branch block (RBBB) to potentially be a “STEMI equivalent” finding to indicate acute
reperfusion, because of it likely indicating proximal occlusion of the LAD [61].
Notable patterns without contiguous STE can also indicate ACO. Aslanger’s pattern may
present in about 6.3% of NSTEMI patients and represent approximately 13.3% of inferior ACO,
often revealing multivessel disease and resulting in higher mortality risks [62]. Another example
of a noncontiguous STE pattern is the recently published South African flag sign, indicative of a
diagonal occlusion [63]. Isolated posterior MI is commonly missed due to it not presenting on
standard 12 lead ECG with STE, but rather reciprocal changes are seen on anteroseptal leads
with STD, which might require additional V7-V9 leads placed on the posterior chest to
adequately detect [31]
Dynamic ECG findings not showing any ST deviation can also indicate ACO.
Hyperacute T-waves, widely considered a precursor sign of ACO and preceding evolvement to a
STEMI pattern, is described as broad-based, asymmetrical, and tall compared with preceding Rwave, most apparent with ACO of the LAD [64]. In addition, de Winter pattern, widely
considered a “STEMI equivalent”, in part due to its high positive predictive value of ACO, is a
form of hyperacute T-wave with ST depression [65]. Wellens syndrome presents as an ECG
pattern primarily showing biphasic or deeply inverted T-waves in leads V2-V3 requiring early
recognition as it represents a pre-infarction state of the LAD, with previous reports of 75% of
patients developing infarction without definitive PCI intervention [66]. Shark fin appearance
caused by fusion of QRS, ST-segment, and T waves, is another high-risk pattern reflecting
presence of large area of transmural ischemia and predicting significant mortality [67].
Furthermore, serial ECGs obtained over 15-30 minute intervals over the first hour might be
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required to capture some of the dynamic changes that occur in an AMI, and has been shown to
improve the sensitivity for STEMI and ACS [68]. Other high-risk criteria potentially indicating
ACO include (transient STE, poor QRS voltage, resting U wave inversions, multiple leads
showing STD and/or significant magnitudes of STD, etc..) summarized in Table 1 [51]. Images
of ECG signs by suspected culprit coronary artery are presented in the appendix (Fig. 2-Fig. 5)
[51].
ECGs can be inconclusive and utilization of clinical, laboratory, and imaging
characteristics to identify high risk NSTEMI patients with ACO can aid in timely definitive
treatment. Utilizing data from 17,739 NSTEMI patients with totally occluded coronary arteries
revealed approximately 70% were male and a majority were between 58-69 years old [7,13].
Risk factors like hypertension, diabetes mellitus, dyslipidemia, and smoking use were also
associated with increased occlusion in NSTEMI patients. Characteristics of chest pain such as
severity, duration, number of episodes, and persistence despite medical treatment raise suspicion
for ACO as well.
Echocardiograph findings can also aid in determining high risk NSTEMI patients, since
changes can present prior to ECG changes or development of symptoms [69]. Regional wall
motion abnormalities on echocardiography localize to territories of occluded coronary arteries
and can be visualized by abnormalities in segmental motion described as hypokinetic, akinetic,
or dyskinetic. Reduced left ventricular ejection fraction, new or worsening mitral regurgitation,
and new ventricular septal defects have been recognized as markers of risk severity in NSTEMI
patients [5,70]. Determining myocardial strain through speckle-tracking echocardiography has
also been used to identify ACO with high accuracy when territorial circumferential strain value
was >-10% [71].
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Other imaging modalities for NSTEMI patients with possible occlusions include
computed tomography (CT) coronary angiography. Results from the follow up study of the
VERDICT trial showed CT coronary angiography to be equivalent to invasive coronary
angiography in differentiating obstructive and nonobstructive coronary artery disease, thus being
a potential timely non-invasive approach to aid in definitive diagnosis [72].
OMI/NOMI Paradigm
A classification system other than STEMI/NSTEMI for ACS has been proposed [73] An
accurate proposal is one that considers the pathophysiologic substrate, which would be an acute
coronary occlusion MI vs non-acute coronary occlusion MI, or to put it shortly occluded MI vs
non-occluded MI (OMI vs NOMI). OMI conceptually equating to an acute coronary occlusion or
near occlusion with insufficient collateral circulation, such that downstream myocardium will
undergo imminent infarction without emergent reperfusion. NOMI refers to an AMI without
angiographic, laboratory, or clinical evidence of OMI, or using the current paradigm, an
NSTEMI without occlusion. Utilizing the OMI/NOMI framework does not only limit to ECG
interpretations, which can sometimes be nondiagnostic, but also includes diagnosis via
biomarkers, echocardiography, computed tomography, and/or conventional angiography [50].
Definitions that come about with introducing the new paradigm whilst including the
current guidelines are as follows. STEMI (+) OMI is a true positive STEMI, which means it
meets current STEMI criteria and is found to have OMI as the cause of the STE and AMI.
STEMI (-) OMI refers to patients that do not meet ECG STEMI criteria but have an occlusion
(an NSTEMI with occlusion). False positive STEMI refers to those meeting STEMI criteria, but
the STE is not due to ischemia and there is absence of OMI on angiogram. The ACS spectrum
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using primarily STEMI/NSTEMI paradigm and OMI/NOMI paradigm are displayed in the
appendix (Fig. 6, Fig. 7) [74].
Meyers et al., retrospectively reviewed 467 high-risk ACS patients and directly compared
STEMI/NSTEMI with the OMI/NOMI paradigm [74]. OMI was defined as an acute culprit and
either TIMI 0-2 flow or TIMI 3 flow plus peak troponin T > 1.0 ng/mL. Out of the 467 high-risk
ACS patients 234 had an AMI (50.1%). In total 108 met OMI criteria with 67 being STEMI (+)
(62%) and 41 being STEMI (-) (38%). Median peak troponin T between STEMI (+) OMI was
similar to STEMI (-) OMI (5.36ng/mL vs. 4.44ng/mL). Rates of new or presumed new wall
motion abnormalities was similar as well (86% vs. 75%). A composite outcome of
catheterization cardiac arrest, in-hospital mortality, or survival with discharge to hospice was
18% and 15% between STEMI (+) OMI and STEMI (-) OMI. Median time from arrival to cath
was delayed in STEMI (-) OMI patients (437 vs. 41 minutes), with only 28% undergoing cath in
less than 90 minutes compared to 76% in the STEMI (+) OMI group (p<0.001).
Meyers et al., recently performed a retrospective case control study of 808 patients with
suspected ACS symptoms and compared structured expert ECG interpretation suggestive of OMI
to STEMI criteria for the diagnosis of an OMI [75]. OMI was defined as either an acute culprit
artery with TIMI flow of 0-2, or a culprit artery with TIMI flow 3 with peak troponin
T ≥1.0 ng/mL or I ≥10.0 ng/mL. The expert ECG findings considered these 8 other findings
highly suggestive of OMI, “subtle STE not meeting criteria, hyperacute T waves (including de
Winter pattern), reciprocal ST depression and/or negative hyperacute T waves, STD maximal in
V1-V4 indicative of posterior OMI, suspected acute pathologic Q waves (meaning Q waves
associated with subtle STE which cannot be attributed to old MI), terminal QRS distortion
(absence of S-wave preceding any subtle STE, where an S-wave would be expected), any STE in
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inferior leads with any STD or T wave inversion in lead aVL, and positive modified Sgarbossa
criteria (MSC) for a patient with left bundle branch block (LBBB) or ventricular paced rhythm
(VPR)” . In total 49% had an AMI with 265 (33%) having an OMI, and only 41% of total OMI
patients meeting STEMI criteria. The results showed higher sensitivity, and similar specificity
using OMI criteria compared to STEMI criteria among the two interpreters (Interpreter 1
sensitivity 86% vs 41%, specificity 91% vs 94%), (Interpreter 2 sensitivity 80% vs 36%,
specificity 92% vs 91%). Inter-rater reliability was high between interpreters with a 97.2%
(kappa value of 0.893) for determining STEMI criteria and 94% agreement for the diagnosis of
OMI (kappa value of .849). OMI criteria lead to correctly identifying 146 (55%) of OMI patients
an average of 3 hours and median of 1.5 hours earlier than using STEMI criteria. Out of the 146
patients with OMI, 120 never met STEMI criteria on any serial ECG recordings. Most common
OMI ECG findings were subtle STE not meeting STEMI criteria (83%) and reciprocal ST
depression and/or reciprocal T-wave inversion (82%). The STEMI (-) OMI patients had similar
infarct sizes as STEMI (+) OMI patients (average peak TnT ng/mL 5.29 vs 6.06) but had greater
delays to angiography with average time to cath (1,181 minutes vs. 265 minutes) and less
undergoing cath <90 minutes from presentation (38% vs. 71%).
The DIFOCCULT study also compared the OMI/NOMI approach versus
STEMI/NSTEMI and was the largest designed study to date challenging the current paradigm
[10]. It was a single center, retrospective case control study of adult patients presenting to the
emergency department clinically for ACS at a tertiary care center for PCI in Turkey. Utilizing
the fourth universal definition of MI, the three groups were STEMI, NSTEMI, Control (ACS
excluded). ACO was defined by total occlusion or presence of culprit lesion on angiography with
peak troponins I level equal to or greater than 1.0ng/ml + an at least 20% rise within 24 hours, a
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highly elevated peak troponin (greater than 5.0 ng/ml), or cardiac arrest before any troponin rise
has been documented with supporting clinical evidence of possible ACO. The study ruled out
15,510 ACS patients by serial troponin, and had 1,152 patients with STEMI, 2,352 with
NSTEMI. Using 1,000 patients for each group analysis, those initially classified as having
NSTEMI, 282 (28.2%) were re-classified by ECG reviewers as having OMI due to minor STE
with reciprocal STD (215), hyperacute T waves or de Winter’s patterns (35), subtle anterior STE
(18), nonconsecutive STE (14). Inter-observer agreement was high for detecting these subtle
ECGs (kappa=0.834). Reclassified NSTEMI had a frequency of ACO of 60.9%, while the
frequency of ACO in STEMI was 85.3%. Myocardial damage by 24 to 48 hour troponin I
measure showed reclassified NSTEMI had (5.703ng/ml), STEMI: (32.990 ng/ml), nonreclassified NSTEMI: (0.622ng/ml). Mortality rates were similar between reclassified NSTEMI
and STEMI in hospital (5.0% vs. 8.3%), and long-term (10.6% vs. 13.7%). In terms of
diagnostic accuracy for ACO after weighted values corrected for real admission rates of each
group the OMI/NOMI approach was overall superior to STEMI/NSTEMI with sensitivity
(67.9% vs. 54.4%), specificity (96.7% vs. 99.0%), positive predictive value (68.2 vs. 43.4), and
negative predictive value (96.6 vs. 94.9). In addition, accuracy for long term mortality weighted
was also shown to be overall higher using the OMI/NOMI approach compared to
STEMI/NSTEMI with sensitivity (64.6% vs. 50.4%), specificity (91.4% vs. 88.8%), positive
predictive value (11.4 vs. 7.1), and negative predictive value (99.3 vs. 99.1). In this study, 17.9%
of ACO in the NSTEMI group were still missed.
Implementing teaching of more subtle ECG findings included under the OMI/NOMI
paradigm has been successfully done and has even lead to outcome improvement. A recent
multi-centre quality improvement initiative to educate emergency physicians on OMI ECG
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findings was done to reduce diagnostic time for patients presenting with ACO [48]. First
emergency department ECG to the time a Code STEMI was activated, or ECG-to-Activation
(ETA) time, was measured to reflect emergency physician clinical decision making. Also,
percentage of Code STEMIs without culprit lesions was measured. Education was primarily
done through weekly web-based feedback on unnecessary cath lab activations and on STEMIequivalents/subtle occlusion findings. ETA time was reduced by 20 minutes, from 28.0 (95%
confidence interval [CI] 15.0–45.0) to 8.0 (95% CI 6.0–15.0), which is clinically significant, and
was done without increasing the percentage of Code STEMIs without culprit lesions; baseline of
28.2% (95% confidence interval [CI] 17.8 to 38.6) and interventional period 20.0% (95% CI
11.2 to 28.8). The most common improvement in ECG diagnosis of ACO was subtle LAD
occlusion (e.g. borderline anterior ST elevation with convex ST segments, hyperacute T waves
or reciprocal changes), subtle inferior MI (minor inferior ST elevation with reciprocal ST
depression in aVL), and posterior MI (anterior ST depression with minor posterior ST elevation).
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Methods
Literature review was first conducted utilizing Dr. Smith’s ECG Blog, under which OMI
relevant literature is compiled. Meyers and Smith’s “OMI Manifesto” served as the initial
principal source for journal articles relevant to STEMI/NSTEMI and OMI/NOMI literature.
Independent review of the cited literature was performed. Personal analysis of original studies
allowed for deeper understanding and verification of material accuracy. In addition, literature
searches were conducted primarily using PubMed literature database and Google Scholar.
Keywords for searches included “ACS”, “STEMI vs NSTEMI”, “STEMI”, “NSTEMI”, ”OMI vs
NOMI”, “OMI”, “NOMI” were performed. Articles that were relevant to the thesis topic were
reviewed and included. Searches were limited to articles in which access to full texts could be
obtained. The Augsburg University’s Lindell Library interlibrary loan was utilized to obtain
some articles. Figures and tables from several articles that were found useful were included in
the Appendix.
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Discussion
The objective of this paper was to conduct an evaluation of the current AMI paradigm
STEMI/NSTEMI and compare it to the newly emerging paradigm OMI/NOMI for evaluation of
patients presenting with ACS to determine whether a new paradigm would result in better
outcomes. Although the research is still limited, there are several findings that ultimately point
towards the benefits of using the OMI/NOMI paradigm.
Shortfalls of STEMI/NSTEMI
When examining the historical development of STEMI/NSTEMI criteria to diagnose
ACO there is clearly poor methodology that has led to the adoption of it into current guidelines.
Ushering in the era of reperfusion therapy in part due to placebo-controlled trials utilizing
thrombolytics, without subset analysis, showed that patients benefited when presenting with
symptoms associated with ACS. ECGs were used to further analyze who would benefit the most
from lytics, however, in the meta-analyses the definitions of “STE”, “STD”, and “normal” were
poorly defined and varied substantially between the RCTs [2]. In addition to poorly defined
metrics, the lack of angiography evidence of ACO in the studies did not prove if in fact STE
patients, who were shown to have decreased mortality with thrombolytics, had pathology
warranting emergent reperfusion. The results do suggest that overall, the STE subgroup likely
had more ACO patients, thus benefiting more from thrombolytics, but still neglects false
positives in the group and false negatives in the non-STE group. The studies showing
thrombolytics are beneficial in AMI patients should have been taken as mere beginning to risk
stratifying ACO patients, but instead led to STEMI being synonymous with ACO requiring
emergent reperfusion therapy. Research refining STE criteria was also done without proper
methodology incorporating angiographic evidence of occlusions, but rather dependent on
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biomarker positivity, which lacks sensitivity for ACO. Evaluating the historical research
revealed that AMI diagnosed by biomarkers is the outcome that was utilized to determine ECG
findings and fine tune STEMI criteria, disregarding any other potential ECG findings of ACO in
the process. Using angiographic evidence to correlate with ECG findings would have been a
better approach in assessing patients presenting with ACO, because then determining who would
benefit most from emergent reperfusion therapy could be made.
When examining the accuracy of STEMI/NSTEMI for discovering ACO, the evidence
shows that it misses approximately 25-30% of ACO in NSTEMI presenting patients, and
sometimes even as high as 50% in ECG silent coronary arteries like the Left circumflex [6, 29].
STEMI criteria results in almost 14-36% of false cath lab activations in patients that are found to
not have culprit lesions [41-42]. With patients that undergo false positive activation the risks
outweigh the benefits, with possible exposure to complications of coronary angiography
including coronary dissections, perforations, early diagnostic closure, arterial punctures, contrast
associated nephropathy, bleeding complications, and large costs. The accuracy of interpretation
by both computer algorithm identification and amongst expert clinicians, including cardiologists,
shows that it has low specificity and sensitivity to be useful in diagnosing ACO [40]. In addition,
reliance on computer interpretation can miss many dynamic changes and other morphologies
indicative of ACO, yet clinicians often find readings of “Normal” as a reassuring sign. It is often
on next day angiography that NSTEMI patients with ACO are discovered, which leads to almost
double short- and long-term mortality compared to NSTEMI patients without occlusion [13]. It is
clear that the STEMI/NSTEMI paradigm is inaccurate in diagnosing ACO, and detrimental to the
NSTEMI patients with ACO that are routinely missed.
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As a cognitive roadblock the STEMI/NSTEMI paradigm continues to undermine
progress in several ways. It presents itself in a way that makes one think that STE on ECG is the
most important marker of ACO, disregarding any other potential ECG findings that investigators
have found to be indicative of ACO with high accuracy [51]. Furthermore, when the ECG is nondiagnostic, focus on other clinical, laboratory, and imaging findings can be valuable in
determining high risk individuals needing emergent reperfusion, but current guidelines simply
fail to emphasize the use of them [51,72]. Classifying patients based on a surrogate marker,
which STEMI/NSTEMI does, misses the underlying pathology of acute coronary occlusion, and
misses the bigger picture of what needs to be determined clinically; who needs emergent
reperfusion therapy and who does not? Improvements via retrospective analysis to improve ACO
discovery is also rather difficult under the current paradigm since we are taught lack of STE is a
reassuring sign, disregard the harms in missing STEMI (-) OMI patients, and group NSTEMI
patients as one homogenous group even when ACO is discovered later in the clinical course.
OMI/NOMI as a Better Paradigm
To improve outcomes in patients with ACO the underlying pathology must be the center
of a paradigm. OMI/NOMI is an emerging paradigm that can do that, by OMI conceptually
equating to as an acute coronary occlusion or near occlusion with insufficient collateral
circulation, such that downstream myocardium will undergo imminent infarction without timely
reperfusion. OMI emphasizes the underlying pathology and so in return utilizes all diagnostic
factors including many other ECG findings, biomarkers, echocardiography, computed
tomography, or conventional angiography [51].
It has been shown that the OMI/NOMI approach using other ECG findings indicative of
ACO compared to STEMI/NSTEMI criteria results in more accurate diagnosis of ACO [74-75].
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Comparing STEMI (-) OMI patients to STEMI (+) OMI patients shows similar infarct sizes and
mortality risks, yet delayed time to angiography. With the OMI/NOMI approach earlier
diagnosis of ACO was achieved in 55% of the OMI cohort on average 3 hours earlier and a
median of 1.5 hours than using the STEMI/NSTEMI model [75]. It is also evident that ECG
interpretation can be improved upon through educational feedback programs for emergency
physicians, which has shown to decrease cath lab activation time with more accurate
interventions [48]. Taking the current literature together suggests that ultimately using the
OMI/NOMI model leads to a more accurate and timely diagnosis in patients presenting with
potential ACO, leading to earlier definitive intervention and thus improved mortality and
morbidity outcomes.
Limitations
Limitations of the research on OMI/NOMI compared to STEMI/NSTEMI exist. The
research directly comparing the two paradigms were primarily retrospective which can create
bias, external validity issues, and long term follow up data difficult to generalize. One of the
bigger limitations is that a randomized clinical trial of immediate vs. delayed angiography is
needed to determine if STEMI (-) OMI patients would indeed undergo earlier intervention than
STEMI (+) OMI patients and have improved outcomes. With OMI/NOMI paradigm and
proposed algorithm still showed 17.9% of ACO is missed [10]. However, by moving to a
paradigm that is more open to discovering new ECG findings and utilizing other factors
indicative of ACO, that number will likely go down. ECG interpretation is subjective and
requires experience for accurate interpretation. The subtleties and complexities associated with
the other ECG findings suggestive of ACO will likely make the OMI/NOMI approach more
difficult to novice interpreters. Furthermore, ECG findings need to be interpreted in the clinical
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context as well. But it has also been shown that clinicians can adapt and broaden their ECG
understanding to improve diagnosis ability [48]. By instituting the OMI/NOMI paradigm
potentially new trials can be performed, the research can be furthered, and ultimately patients can
benefit in the long run. Indeed, future results are always contingent on parameters outside merely
diagnosing ACO, and improvements in factors such as revascularization procedures and post
cardiac rehabilitation will be vital in treating patients and improving outcomes as well.
Conclusion:
ACS continues to be a significant proportion of patients presenting to emergency
department, yet our current dichotomous STEMI/NSTEMI paradigm fails to adequately capture
all of the patients requiring emergent reperfusion therapy. Examining the historical context in
which STEMI/NSTEMI was developed reveals flawed methodology that has nevertheless led to
it becoming the dogmatic approach to determining who has ACO requiring emergent reperfusion
therapy. Furthermore, as a paradigm it fails to progress the knowledge of ACO and hinders a
substantial amount of ACS patients from receiving definitive treatment. With nearly 30% of
NSTEMI patients having totally occluded coronary arteries determined on delayed angiography
the need for a paradigm shift to capture these patients is required to improve outcomes. Focusing
on an ECG surrogate marker of ACO fails to consider the underlying pathophysiology. The
OMI/NOMI paradigm is more inclusive of other ECG findings shown to be highly accurate
indicators of ACO, as well as use of echocardiography, biomarkers, computed tomography, and
conventional angiography. When the OMI/NOMI paradigm approach of ECG interpretation was
compared to STEMI/NSTEMI, earlier and more accurate diagnosis was made. Furthermore,
when other ACO indicative ECG findings under the OMI/NOMI model were taught to
emergency physicians, cath lab activation was faster and more accurate supporting its usefulness
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as a model. The findings presented in this paper suggest the OMI/NOMI paradigm can
successfully improve outcomes in patients presenting to the ED with ACS, but future
randomized clinical trials are needed to answer that question more definitively.
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Appendix

Figure 1. A timeline of major events providing insights into the acute myocardial infarction
pathogenesis and management [17].
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Table 1. Electrocardiographic signs indicative of non-ST elevation myocardial
infarction with total occlusion of the culprit coronary artery [51].
Non-coronary specific signs
Total number of leads showing ST-segment depression (>3)
Total ST-segment depression sum (≥ 6 mm)
ST-segment depression > 2 mm in any lead
Presence of q waves in ≥ 2 contiguous leads
Hyperacute T waves
‘Shark-fin’ – triangular waveform ECG pattern
Transient ST-segment elevation
Low QRS voltage
LAD specific signs
Hyperacute T waves
De Winter's sign
Wellens' sign (Type A & Type B)
‘Shark-fin’ – triangular waveform ECG pattern
New RBBB
Resting U-wave inversion
LCx specific signs
ST-segment depression and/or T-wave inversion in inferolateral leads
ST-segment depression in V1-V3 leads
ST-segment elevation in V7-V8 leads
Prominent R-waves in V1-V2 (R/S > 1) with upright T waves V1-V3
RCA specific signs
ST-segment depression and/or T-wave inversion in inferolateral leads
ST-segment depression in V1-V3 leads
ST-segment elevation in V7-V8 leads
Prominent R-waves in V1-V2 (R/S > 1) with upright T waves V1-V3
ST-segment elevation in lead V4R
ST-segment elevation in lead V1
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Deep ST-segment depression in lateral leads (I + aVL ≥ 2 mm & ST depression aVL
> I)
QRS prolongation or epsilon wave in lead V4R
LM specific signs
ST-segment elevation in aVR lead
ST-segment depression in all leads
ST-elevation in lead aVR ≥V1
‘Shark-fin’ – triangular waveform ECG pattern
Other high-risk signs
New RBBB
Myocardial infarction on previous LBBB using Scarbossa criteria
AV conduction abnormalities
AV; atrioventricular, ECG; electrocardiogram, LBBB; left bundle branch block, RBBB, right
bundle branch block.
New LBBB is considered as STEMI by definition and requires urgent coronary angiography.
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Figure 2. Left anterior descending coronary artery ECG specific signs [51]

Figure 3. Left circumflex coronary artery ECG specific signs [51]
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Figure 4. Right coronary artery ECG specific signs [51]

Figure 5. Left main coronary artery ECG specific signs [51]
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Figure 6. The acute coronary syndrome (ACS) spectrum using the ST-segment elevation
myocardial infarction (STEMI) vs. nonSTEMI paradigm primarily. The current paradigm of MI divides acute MI into STEMI and
non-STEMI based on the electrocardiogram (ECG). Occlusion myocardial infarction (OMI) and
nonocclusion myocardial infarction (NOMI) are possible in both STEMI
and non-STEMI categories. [74]
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Figure 7. The acute coronary syndrome (ACS) spectrum using the occlusion myocardial
infarction (OMI) vs. nonocclusion myocardial infarction (NOMI) paradigm primarily. The
proposed paradigm of MI divides acute MI into OMI and NOMI. OMI are those for whom
thrombolytics and percutaneous coronary intervention were conceptually designed and indicated,
but many OMI do not manifest ST-segment elevation myocardial infarction (STEMI) criteria.
ECG = electrocardiogram. [74]

